Next Generation in Protein Characterization
Aggregation
Quantitation
Stability
Structure
Similarity
"RedShiftBio provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality."
The Journal of Pharmaceutical Sciences published a paper authored by a team at Pfizer featuring the AQS3™pro
The Next Generation in Protein Characterization
The AQS3pro brings protein secondary structure measurement into every stage of the biopharmaceutical pipeline. Measuring in conditions that were previously not possible with traditional methods, The AQS3pro provides repeatable, high sensitivity, automated measurement across a wide concentration range, in any formulation.
See change in your protein, in your workflow, and in your efficiency.
Register below for on demand webinars
Join Us For Our Monthly Webinars Introducing Microfluidic Modulation Spectroscopy
Latest News
RedShiftBio Appoints Primetech as Exclusive Distributor in Japan
RedShiftBio Appoints Topbiox as Exclusive Distributor in China
RedShiftBio Appoints Julien Bradley as new CEO
RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization.
Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS3pro.
RedShiftBio®
RedShiftBio® is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.
Awards
Contact Us
RedShift BioAnalytics Inc.
131 Middlesex Turnpike
Burlington, MA 01803
T: 781.345.7300
F: 781-345-7301
E: info@redshiftbio.com
RedShift™, RedShiftBio®, See Change®, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.